Risk of myocardial infarction and abacavir therapy: No increased risk across 52 glaxosmithkline-sponsored clinical trials in adult subjects

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 1, 2009, Pages 20-28

  Brothers, Cindy H ^a   Hernandez, Jaime E ^a   Cutrell, Amy G ^a   Curtis, Lloyd ^a   Ait Khaled, Mounir ^a   Bowlin, Steve J ^b   Hughes, Sara H ^a   Yeo, Jane M ^a   Lapierre, Didier H ^a,c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GlaxoSmithKline Global Clinical Safety and Pharmacovigilance ^*  (Belgium)

Author keywords

Abacavir; Coronary artery disease; Myocardial infarction

Indexed keywords

ABACAVIR;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 67651167085     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819ff0e6     Document Type: Article

References (35)

1. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet. 2000;355:1158-1159.
2. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet. 2000;356:291-296.
3. Hooshyar D, Hanson DL, Wolfe M, et al. Trends in perimortal conditions and mortality rates among HIV-infected patients. AIDS. 2007;21:2093-2100.
4. Casau N. Perspective on HIV and aging: emerging research on the horizon. Clin Infect Dis. 2005;41:855-863.
5. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother. 2006;57:4-7.
6. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002;16:1663-1671.
7. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005;34:121-330.
8. Lewden C, May T, Rosenthal E, et al. Causes of death among HIVinfected adults in France in 2005 and evolution since 2000. Presented at:14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA. Abstract 976.
9. Stein JH, Cotter BR, Parker RA, et al. Antiretroviral therapy improves endothelial function in individuals with human immunodeficiency virus infection: a prospective, randomised multicenter trial (Adult AIDS Clinical Trials Group Study A5152s). Circulation. 2005;112:II-237.
10. Oh J, Hegele RA. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis. 2007;7:787-796.
11. Friis-Müller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
12. The D:A:D Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
13. DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417-1426.
14. Almenoff JS. Innovations for the future of pharmacovigilance. Drug Saf. 2007;30:631-633.
15. Sanz E. Abacavir-myocardial infarction. WHO Signal May 4-6 2005. Available at: http://www.who-umc.org/graphics/15962.pdf. Accessed April 14, 2008.
16. Podzamczer C, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2007;44:139-147.
17. deWit S, Sabin C, Weber R, et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D Study [published online ahead of print February 11, 2008]. Diabetes Care. doi:10.2337/dc07-2103.
18. Ledergerber B, Furrer H, Rickenbach M, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the HIV Swiss Cohort Study. Clin Infect Dis. 2007;45:111-119.
19. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005; 19:1375-1383.
20. Smieja M, Lonn E, Smaill F, et al. Associations of proteases inhibitors and stavudine with carotid intima media thickness in the Canadian HIV Vascular Study. Presented at: 16th Annual Canadian Conference on HIV/AIDS Research; April 26-29, 2007; Toronto, Ontario. Abstract 0039.
21. The SMART Study Group. CD 4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296.
22. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet. 2006;368:459-465.
23. Calmy A, Nguyen A, Montecucco F, et al; for the STACCATO Study Team. HIV activates markers of cardiovascular risk in a randomized treatment interruption trial: STACCATO. Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 140.
24. Hughes MD, Williams PL. Challenges in using observational studies to evaluate adverse effects of treatment. N Engl J Med. 2007;356:1705-1707.
25. Daluge SM, Good SS, Faletto MB, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother. 1997;41:1082-1093.
26. Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/ nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral- naïve patients: effect of sex and ethnicity. HIV Med. 2006;7:85-98.
27. Sutherland-Phillips DH, Hernandez JE, Wannamaker PG, et al. Differential effects of nucleoside reverse transcriptase inhibitors (NRTI) with and without a protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) on lipid parameters. Presented at: 8th International Clinical Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; September 24-26, 2006; San Francisco, CA. Poster No. 69.
28. Tashima K, Kumar P, Rodriguez-French A, et al. Gender and race subgroup analyses in 4 large, randomised clinical trials comparing abacavir (ABC) to protease inhibitors (PI) or zidovudine (ZDV) in ART-naïve subjects. Presented at: the 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; September 24-26, 2006; San Francisco, CA. Poster No. 96.
29. Shikuma CM, Yang Y, Glesby BY, et al. Metabolic effects of protease inhibitor sparing regimen given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007;44:540-550.
30. Castillo S, Hernandez J, Brothers C. Long term safety and tolerability of the lamivudine/ABC combination as components of highly active antiretroviral therapy. Drug Saf. 2006;29:811-826.
31. Smith K, Fine D, Patel P, et al. Efficacy and safety of ABC/lamivudine compared to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT Study. Presented at:15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 774.
32. Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz or ABC for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036-1046.
33. Keiser PH, Sension MG, DeJesus E, et al. Substituting hyperlipidemiainducing protease inhibitors with ABC improves lipid profiles, maintains virologic suppression and simplifies treatment. BMC Infect Dis. 2005;5:2.
34. European AIDS Clinical Society (EACS) Guidelines for the clinical management and treatment of HIV Infected Adults in Europe. 2007. Available at: http://www.eacs.eu/Guidelines-Livret/index.htm. Accessed February 27, 2009.
35. WHO antiretroviral therapy for HIV infected adults and adolescents in resource limited settings: towards universal access, recommendations for a public heath approach. 2006 revision. Available at: http://www.who.int/hiv/pub/ guidelines/art/en/index.html. Accessed February 27, 2009.